CN115612637A - 一株植物乳杆菌及其应用 - Google Patents
一株植物乳杆菌及其应用 Download PDFInfo
- Publication number
- CN115612637A CN115612637A CN202210887575.4A CN202210887575A CN115612637A CN 115612637 A CN115612637 A CN 115612637A CN 202210887575 A CN202210887575 A CN 202210887575A CN 115612637 A CN115612637 A CN 115612637A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- sxp08
- lactobacillus
- ulcerative colitis
- cgmcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 69
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 69
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 69
- 230000000968 intestinal effect Effects 0.000 claims abstract description 28
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 17
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 11
- 241000186660 Lactobacillus Species 0.000 claims abstract description 8
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 14
- 244000005700 microbiome Species 0.000 abstract description 14
- 239000006041 probiotic Substances 0.000 abstract description 7
- 230000000529 probiotic effect Effects 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 6
- 108010062877 Bacteriocins Proteins 0.000 abstract description 5
- 241000588724 Escherichia coli Species 0.000 abstract description 5
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 abstract description 2
- 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 10
- 229960004963 mesalazine Drugs 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 229920003045 dextran sodium sulfate Polymers 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- 241000192142 Proteobacteria Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000007924 bacterial virulence factor Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 241000702460 Akkermansia Species 0.000 description 2
- 241000605059 Bacteroidetes Species 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241000125969 Lachnoclostridium Species 0.000 description 2
- 241001112693 Lachnospiraceae Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241001261005 Verrucomicrobia Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000012268 genome sequencing Methods 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 239000004267 EU approved acidity regulator Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008918 emotional behaviour Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Communicable Diseases (AREA)
Abstract
本发明公开了一株植物乳杆菌及其应用，属于微生物技术领域，涉及乳杆菌。一株植物乳杆菌Lactobacillus plantarumSXp08，保藏在中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC NO.24928，保藏日期为2022年5月19日。本发明植物乳杆菌SXp08具细菌素基因达31个，抑菌范围广，可体外抑制大肠杆菌、金黄色葡萄球菌等多种细菌，具有良好的益生功能，可高密度培养，能有效改善溃疡性结肠炎小鼠的肠道菌群结构，缓解DSS诱导的溃疡性结肠炎。
Description
技术领域
本发明属于微生物技术领域，涉及乳杆菌，具体涉及一株植物乳杆菌及其在调节肠道菌群中的应用。
背景技术
人体肠道内所含的微生物数量超过10万亿个，约占人体微生物总量的78.68%，数量巨大的肠道微生物共同组成了人体肠道微生态系统。该系统与人体健康息息相关，可从消化、营养吸收、能量供应、脂肪代谢、抗病等多方面影响宿主的生理功能，不仅可以帮助宿主消化食物、代谢药物以及外源化合物、合成维生素、抑制病原体的侵袭，还可影响免疫系统发育和大脑活动，甚至可以调控宿主的情绪行为。
越来越多的研究结果表明，肠道微生态系统的平衡对宿主健康起重要作用。当肠道微生物菌群结构失衡时，部分肠道微生物会对宿主的健康产生负面影响，而且众多人体疾病的病发与肠道微生物的异常相关联。如心脑血管疾病、肥胖、糖尿病、炎症性肠炎（IBD）、肠易激综合症（IBS）、胃肠道癌症、肝硬化、慢性肾病等病症的发生都与肠道微生物的异常有关。
为了保持肠道微生态系统的平衡，抑制肠道有害菌的生长，本发明筛选了一株植物乳杆菌（Lactobacillus plantarum），以达到上述目的。
发明内容
本发明的目的是提供一株植物乳杆菌。
本发明的再一个目的是提供植物乳杆菌的的应用。
本发明是通过以下技术方案实现的：
一株植物乳杆菌Lactobacillus plantarumSXp08，保藏在中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC NO. 24928，保藏日期为2022年5月19日。
所述的植物乳杆菌SXp08在制备抑菌、防腐制品中的应用。
所述的植物乳杆菌SXp08在制备调节肠道菌群的药品、和/或保健品、和/或饲料中的应用。
所述的植物乳杆菌SXp08在制备治疗溃疡性结肠炎药物中的应用。
进一步地，在上述应用中，包括了植物乳杆菌SXp08活菌体的的培养物、菌悬液或裂解物。
更进一步，在上述应用中，所述的活菌体数≥1×1010CFU/mL。
本发明通过碳酸钙溶钙圈筛选得到植物乳杆菌SXp08，具有很好的耐酸、耐胆盐胁迫能力和较强的抗氧化、分解胆固醇的益生功效，其16s rRNA基因序列在GeneBank中进行比对，结果显示为植物乳杆菌，命名为植物乳杆菌（Lactobacillus plantarum）SXp08，将SXp08接种在MRS液体培养基中，在30~37℃下培养18~24 h，提取活菌体进行细菌基因组测序分析，发现其具有30种、31个细菌素基因，无CARD抗生素抗性基因和VFDB细菌毒力因子基因，其可用于制备调节肠道菌群的药品、和/或保健品、和/或饲料。
通过抑菌圈实验，发现植物乳杆菌培养液、细胞裂解液、培养上清液对大肠杆菌、金黄色葡萄球菌、枯草芽孢杆菌、沙门氏菌、克雷伯氏菌等不同菌株具有明显的抑制效果；其可用于制备抑菌、防腐制品。
使用ICR小鼠，通过饮用葡聚糖硫酸钠建立溃疡性结肠炎模型, 比较正常对照组、模型对照组、植物乳杆菌SXp08治疗组和美沙拉嗪治疗组小鼠的肠道菌群结构，以小鼠粪便为样本，提取DNA后进行16S rDNA V3~V4区高通量测序。统计不同类型小鼠肠道菌群在门水平和属水平上的分布，植物乳杆菌具有增加厚壁菌门、毛螺菌科 NK4A136 group的相对丰度，降低变形菌门、疣微菌门、拟杆菌属和Akkermansia的相对丰度的作用；正常对照小鼠的肠道微生物平均OTU为685.6，结肠炎模型小鼠为630.5，植物乳杆菌SXp08治疗组为641，美沙拉嗪治疗组为462.8，OUT数越多代表微生物种类越多，植物乳杆菌具有维持肠道微生物多样性的作用，其可以用于制备调节肠道菌群的药品、和/或保健品、和/或饲料。
使用ICR小鼠，通过饮用葡聚糖硫酸钠建立溃疡性结肠炎模型, 比较正常对照组、模型对照组、植物乳杆菌治疗组和美沙拉嗪治疗组小鼠的体重变化、结肠长度、临床症状等方面的差异，发现植物乳杆菌具有改善溃疡性结肠炎的作用，其可以用于制备治疗溃疡性结肠炎的药物。
综上所述，本发明植物乳杆菌SXp08活菌体、发酵液、菌悬液、上清液作为主要成分，可应用于制备各种抑菌产品、调节肠道菌群和改善溃疡性结肠炎的药物、保健品、复合益生菌粉、饲料等，其中植物乳杆菌SXp08的有效活菌数≥1×1010CFU/mL。使用时，可以配以辅料，根据作用对象和用途不同，辅料可以为但不限于各种益生元、保护剂、填充剂、粘合剂、润湿剂、崩解剂、润滑剂、矫味剂、香味剂、着色剂、包衣剂、酸度调节剂、防腐剂、稀释剂、悬浮液稳定剂等。
与现有技术相比，本发明植物乳杆菌SXp08具细菌素基因达31个，抑菌范围广，可体外抑制大肠杆菌、金黄色葡萄球菌等多种细菌，具有良好的益生功能，可高密度培养，能有效改善溃疡性结肠炎小鼠的肠道菌群结构，缓解DSS诱导的溃疡性结肠炎。
附图说明
图1 植物乳杆菌SXp08不同培养温度时的生长曲线。
具体实施方式
为进一步阐述本发明所采取的技术手段及其效果，以下结合实施例对本发明作进一步地说明。此处所描述的具体实施方式仅仅用于解释本发明，而非对本发明的限定。
实施例中未注明具体技术或条件者，按照本领域内的文献所描述的技术或条件，或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者，均为可通过正规渠道商购获得的常规产品。
实施例1
从山西维尔生物乳制品有限公司生牛初乳储藏罐中收集残余牛乳于无菌三角瓶中，用灭菌生理盐水将牛乳样品稀释至10-5，取原液、10-1、10-3、10-5各0.1 mL涂布MRS碳酸钙培养基平板，35 ℃厌氧培养盒培养48h，挑选溶钙圈比较大的单菌落，重复划线分离，挑选单菌落用200 mL/L甘油管-80 ˚C 保藏备用；进一步进行耐酸、耐胆盐、抗氧化能力、分解胆固醇能力的筛选以及菌株的鉴定。
筛选得到的植物乳杆菌Lactobacillus plantarum SXp08，于2022年5月19日保藏在中国微生物菌种保藏管理委员会普通微生物中心（CGMCC），地址为北京市朝阳区北辰西路1号院3号，邮编100101，保藏编号为CGMCC NO.24928。
MRS液体培养基：蛋白胨 10 g /L、牛肉浸膏 5 g /L、酵母浸膏 4 g /L、葡萄糖20 g /L、磷酸氢二钾 2 g /L、乙酸钠 5 g /L、柠檬酸三铵 2 g /L、硫酸镁 0.2 g /L、硫酸锰 0.05 g /L、吐温 80 1.0 mL/L，pH6.5，用蒸馏水定容至 1000 mL，121 ℃灭菌 15min。
MRS固体培养基：MRS液体培养基中加入20 g/L 的琼脂粉，121 ℃灭菌 15 min。
将植物乳杆菌Lactobacillus plantarum SXp08进行耐酸、耐胆盐、抗氧化能力、分解胆固醇能力的测定，测定参照已有方法进行。
菌株的生理生化鉴定参照《常见细菌鉴定手册》和《微生物分类学》，观察各菌株的形态特征，并对菌株进行生理生化实验，对筛选菌株进行初步的分类鉴定。分子生物学鉴定由金唯智公司进行16S rDNA序列测定，将测得的DNA序列提交到GenBank美国国家生物技术信息中心(National Center of Biotechnology Information, NCBI)进行比对。
植物乳杆菌SXp08的菌落直径约1～3 mm左右，凸起，呈圆形，表面光滑，细密，白色；菌体形态呈短杆状、成短链，革兰氏染色为阳性，无芽孢，产酸，兼性厌氧。
实验结果为：植物乳杆菌SXp08通过碳酸钙溶钙圈筛选，pH 2.5条件下处理2h耐酸生长率为63.72%，耐3g/mL胆盐生长率为53.28%；在菌体浓度达到1010 CFU/mL的情况下，DPPH·清除率为43.5%，羟自由基清除率为86.7%，胆固醇分解能力为51.4%。
植物乳杆菌SXp08过氧化氢酶、氧化酶、淀粉水解、明胶液化试验结果呈阴性，甲基红实验结果呈阳性。
植物乳杆菌SXp08 16s rRNA基因核酸序列：
TTTGAACTGAACAAAGTTTCGACGAATCAAATGTGTAGGGTCTCTTGATTTTGAATCAAGAGCAAAACATTTGCGAAGTCAATTCGCTAGCAAATAAATTTTAGTACAACATTAAATGAGCTTTTTAGAACTCATCATTAATTTGAGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCGTGCCTAATACATGCAAGTCGAACGAACTCTGGCATTGATTGGTGCTTGCATCATGATTTACATTTGAGTGAGTGGCGAACTGGTGAGTAACACGTGGGAAACCTGCCCAGAAGCGGGGGATAACACCTGGAAACAGATGCTAATACCGCATAACAACTTGGACCGCATGGTCCGAGTTTGAAAGATGGCTTCGGCTATCACTTTTGGATGGTCCCGCGGCGTATTAGCTAGATGGCGAGGTAACGGCTCACCATGGCAATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGAAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAACTCTGTTGTTAAAGAAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCTTCGGCTCAACCGAAGAAGTGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGTATGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCATACCGTAAACGATGAATGCTAAGTGTTGGAGGGTTTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATACTATGCAAATCTAAGAGATTAGACGTTCCCTTCGGGGACATGGATACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTATCAGTTGCCAGCATTAAGTTGGGCACTCTGGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAACTCGCGAGAGTAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCAAAGTCGGTGGGGTAACCTTTTAGGAACCAGCCGCCTAAGGTGGGACAGATGATTAGGGTGAAGTCGTAACAAGGTAGCCGTAGGAGAACCTGCGGCTGGATCACCTCCTTTCTAAGGAATATTACGGAAACCTACACACGCGTCGAAACTTTGTTTAGTTTTGAGAGATTTAACTCTCAAAACTTGTTCTTTGAAAACTAGATAATATCAAATATATTTTTTCATAATGAAACCGAGAACACCGCGTTTTTTGAGTTTTATGTAGGAACCAGCCGCCTAAGGTATCGA。
实施例2
对实施例1分离得到的植物乳杆菌SXp08的生长能力进行测定，步骤为：将活化好的植物乳杆菌接种于MRS液体培养基中,设定温度下静置培养，每间隔 2 h 取样测定培养液pH和 OD600 值，培养温度范围为30~37℃，培养时间范围为18~24 h，绘制菌体生长曲线图，从图1可以看出在培养温度35℃、培养时间18h时，植物乳杆菌SXp08的菌体密度OD600 值可高达1.96，培养皿活菌计数为5.6×1011 CFU/mL，具有高密度培养的潜质。
实施例3
通过植物乳杆菌SXp08的基因组测序及抑菌圈实验考察植物乳杆菌SXp08的抑菌范围和抑菌效果。
抑菌圈实验通过在培养基上打孔进行，以抑菌圈的大小评价其抑制各种菌生长的能力，其中分别测定了包括植物乳杆菌培养液、细胞裂解液、培养上清液对不同菌株的抑制效果。
其中细菌素基因见表1，同时通过与CARD抗性基因数据库和VFDB细菌毒力因子数据库比对，植物乳杆菌SXp08无CARD抗生素抗性基因和VFDB细菌毒力因子基因，为安全的益生菌菌株。其抑菌作用见表2，从表2可以看出植物乳杆菌SXp08对大肠杆菌、金黄色葡萄球菌、枯草芽孢杆菌、沙门氏菌、克雷伯氏菌等不同菌株具有明显的抑制效果，抑菌范围广，效果明显。
表1 植物乳杆菌SXp08的细菌素基因
表2 植物乳杆菌SXp08对不同菌株的抑制效果
| 被抑制菌种 | 抑菌效果（抑菌圈直径/mm） |
| 大肠杆菌 | 16.22 |
| 金黄色葡萄球菌 | 15.38 |
| 枯草芽孢杆菌 | 17.83 |
| 沙门氏菌 | 16.91 |
| 克雷伯氏菌 | 14.56 |
| 化脓性链球菌 | 16.88 |
| 分支杆菌 | 12.75 |
| 嗜血杆菌 | 13.74 |
实施例4
将24只雄性ICR小鼠根据随机数字表法分为4组:正常对照组（CK）、模型对照组（D）、植物乳杆菌SXp08治疗组（D+P）和美沙拉嗪治疗组（D+A）,每组各6只。模型对照组和两个治疗组通过饮用葡聚糖硫酸钠建立溃疡性结肠炎模型，两个治疗组小鼠分别给予植物乳杆菌SXp08和美沙拉嗪灌胃治疗，正常对照组和模型对照组给予0.9%氯化钠溶液灌胃。14天后取各小鼠的粪便样本、提取DNA，通过16S rDNA V3~V4区高通量测序，考察植物乳杆菌SXp08对溃疡性结肠炎小鼠肠道菌群的调节作用。
4组小鼠的溃疡性结肠炎小鼠肠道微生物多样性的结果见表3，其中OUT数越多代表微生物种类越多，从表3可以看出，植物乳杆菌SXp08治疗组的肠道微生物多样性更丰富。
表3 OTU代表的小鼠肠道微生物多样性
| 小鼠模型 | CK | D | D+P | D+A |
| 肠道微生物平均OTU | 685.6 | 630.5 | 641 | 462.8 |
4组溃疡性结肠炎小鼠肠道微生物菌群结构的结果见表4和表5， 从表4和5可以看出，在门水平上，植物乳杆菌SXp08治疗组（D+P）与模型对照组（D）比较，可以增加厚壁菌门的丰度，降低拟杆菌门、变形菌门、柔膜菌门的丰度；与美沙拉嗪治疗组（D+A）比较可以显著增加厚壁菌门的丰度，降低拟杆菌门、变形菌门、放线菌门、疣微菌门的丰度。在属水平上，植物乳杆菌SXp08治疗组（D+P）与模型对照组（D）比较，可显著提高毛螺菌科NK4A136group、Lachnoclostridium、Ruminiclostridium 9、阿克曼菌属的丰度，降低拟杆菌属的丰度；与美沙拉嗪治疗组（D+A）比较可显著提高毛螺菌科NK4A136 group、Lachnoclostridium、Ruminiclostridium 9的丰度，降低拟杆菌属和阿克曼菌属的丰度。植物乳杆菌SXp08的这些对肠道菌群的调节作用对维护正常的肠道微生态系统是非常重要的。
表4 不同处理小鼠肠道菌群在门水平上的分布
表5 不同处理小鼠肠道菌群在属水平上的分布
实施例5
将实施例4的4组小鼠分别进行体重变化、结肠长度、临床观察的的相关表现进行试验，结果见表6，从表6可以看出，植物乳杆菌SXp08治疗组（D+P）的体重变化不大，而模型对照组（D）和美沙拉嗪治疗组（D+A）的体重都有所降低；植物乳杆菌SXp08治疗组（D+P）的结肠长度大于模型对照组（D）和美沙拉嗪治疗组（D+A）；临床反应优于模型对照组（D）和美沙拉嗪治疗组（D+A）。说明植物乳杆菌SXp08对缓解小鼠溃疡性结肠炎具有一定的作用。
表6 不同处理小鼠溃疡性结肠炎相关表现
实施例6
一种含有植物乳杆菌SXp08酸奶发酵剂的制备，制备方法如下：将植物乳杆菌接种于MRS液体培养基中，35℃下培养24 h进行活化，连续活化2次，得到活化液；将活化液按2%（v/v）的接种量接种于MRS液体培养基中，37℃下培养24 h，得到菌液；将菌液在8000 g下离心10 min，得到植物乳杆菌菌体；将菌体用质量浓度为10%的脱脂奶粉重悬至浓度为1×1010CFU/mL，得到菌悬液；将菌悬液在37℃下预培养1 h后冻干，得到植物乳杆菌SXp08发酵剂。在制备酸奶的时候按1.5g/100mL接种于鲜牛乳中，同时按2g/100mL接种保加利亚乳杆菌和嗜热链球菌发酵剂，由于植物乳杆菌SXp08优良的抑菌作用，使用此种方法制备的活菌酸奶冷藏保质期可延长5天。
实施例7
一种含有植物乳杆菌SXp08复合益生菌粉的制备，制备方法如下：植物乳杆菌SXp08经斜面活化后，接种于10 L种子罐，35 ℃培养16 h，按接种量20 mL/L接种于100 L发酵罐中，起始pH 6.5、培养温度35 ℃、溶氧0 mL/L（控制在100 mL/L以下）、搅拌转速50 r/min、罐压0.03 Mpa、发酵培养20 h；发酵结束后，将发酵液通过运输管道打入管式离心机中，10000 r/min连续离心20 min制备菌泥；以低聚果糖5g/100 mL、脱脂乳粉12.5g/100mL、半乳糖4.5g/100 mL、乳糖 3g/100 mL、脯氨酸2.5g/100 mL、水溶性海藻糖3g/100 mL为冻干保护剂制备植物乳杆菌冻干份；该冻干粉活菌数可达1011 CFU/g。植物乳杆菌SXp08冻干粉可复配乳双歧杆菌、植物乳杆菌、嗜酸乳杆菌、鼠李糖乳杆菌、副干酪乳杆菌等益生菌，乳糖醇、低聚木糖、赤藓糖醇、甜橙粉、异构化乳糖液等益生元和辅助材料制备复合益生菌粉。
Claims (7)
1.一株植物乳杆菌Lactobacillus plantarumSXp08，保藏在中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC NO. 24928，保藏日期为2022年5月19日。
2.权利要求1所述的植物乳杆菌SXp08在制备抑菌、防腐制品中的应用。
3.权利要求2所述的应用，其特征在于，所述的植物乳杆菌SXp08为活菌体，所述活菌数≥1×1010CFU/mL。
4.权利要求1所述的植物乳杆菌SXp08在制备调节肠道菌群的药品、和/或保健品、和/或饲料中的应用。
5.权利要求4所述的应用，其特征在于，所述的植物乳杆菌SXp08为活菌体，所述的活菌数≥1×1010CFU/mL。
6.权利要求1述的植物乳杆菌SXp08在制备治疗溃疡性结肠炎药物中的应用。
7.权利要求6所述的应用，其特征在于，权利要求1所述的植物乳杆菌SXp08为活菌体，所述的活菌数≥1×1010CFU/mL。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210887575.4A CN115612637B (zh) | 2022-07-26 | 一株植物乳杆菌及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210887575.4A CN115612637B (zh) | 2022-07-26 | 一株植物乳杆菌及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115612637A true CN115612637A (zh) | 2023-01-17 |
| CN115612637B CN115612637B (zh) | 2024-08-02 |
Family
ID=
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116694503A (zh) * | 2023-03-27 | 2023-09-05 | 上海华聿康生物科技有限公司 | 一种具有润肠通便和提高免疫功能的植物乳杆菌Lp-HZ55 |
| CN117683698A (zh) * | 2024-02-04 | 2024-03-12 | 山东中科嘉亿生物工程有限公司 | 一种植物乳杆菌jylp-376及后生元菌剂、制备方法和应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111035661A (zh) * | 2018-10-15 | 2020-04-21 | 深圳市华大农业应用研究院 | 植物乳杆菌的用途 |
| CN111235070A (zh) * | 2020-03-18 | 2020-06-05 | 河北农业大学 | 一株母乳婴儿源植物乳杆菌bf_15及其应用 |
| CN111281895A (zh) * | 2019-12-24 | 2020-06-16 | 顾青 | 用于治疗结肠炎的乳酸菌及其应用 |
| CN113151039A (zh) * | 2021-01-14 | 2021-07-23 | 江南大学 | 一株缓解溃疡性结肠炎的植物乳杆菌及其应用 |
| CN114231443A (zh) * | 2021-11-29 | 2022-03-25 | 大连工业大学 | 一种植物乳杆菌复合菌及其在制备缓解肠道炎症或治疗溃疡性结肠炎复合益生菌中的应用 |
| CN114774327A (zh) * | 2022-05-12 | 2022-07-22 | 河北科技大学 | 一种植物乳杆菌hb13-2及其应用 |
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111035661A (zh) * | 2018-10-15 | 2020-04-21 | 深圳市华大农业应用研究院 | 植物乳杆菌的用途 |
| CN111281895A (zh) * | 2019-12-24 | 2020-06-16 | 顾青 | 用于治疗结肠炎的乳酸菌及其应用 |
| CN111235070A (zh) * | 2020-03-18 | 2020-06-05 | 河北农业大学 | 一株母乳婴儿源植物乳杆菌bf_15及其应用 |
| CN113151039A (zh) * | 2021-01-14 | 2021-07-23 | 江南大学 | 一株缓解溃疡性结肠炎的植物乳杆菌及其应用 |
| CN114231443A (zh) * | 2021-11-29 | 2022-03-25 | 大连工业大学 | 一种植物乳杆菌复合菌及其在制备缓解肠道炎症或治疗溃疡性结肠炎复合益生菌中的应用 |
| CN114774327A (zh) * | 2022-05-12 | 2022-07-22 | 河北科技大学 | 一种植物乳杆菌hb13-2及其应用 |
Non-Patent Citations (4)
| Title |
|---|
| MILAD ABDI等: "Interesting probiotic traits of mother’s milk Lactobacillus isolates; from bacteriocin to inflammatory bowel disease improvement", 《MICROBIAL PATHOGENESIS》, vol. 158, pages 303 - 304 * |
| 史佳鹭等: "益生菌对溃疡性结肠炎影响的研究进展", 《食品科学》, pages 310 - 317 * |
| 张飞: "猪源植物乳杆菌分离鉴定及其益生作用研究", 《中国博士学位论文全文数据库 基础科学辑》, pages 006 - 448 * |
| 陈瑞龙: "植物乳杆菌细菌素高产菌株的诱变选育、抑菌机理及应用", 《中国优秀硕士学位论文全文数据库 工程科技I辑》, pages 024 - 138 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116694503A (zh) * | 2023-03-27 | 2023-09-05 | 上海华聿康生物科技有限公司 | 一种具有润肠通便和提高免疫功能的植物乳杆菌Lp-HZ55 |
| CN116694503B (zh) * | 2023-03-27 | 2024-01-05 | 上海华聿康生物科技有限公司 | 一种具有润肠通便和提高免疫功能的植物乳杆菌Lp-HZ55 |
| CN117683698A (zh) * | 2024-02-04 | 2024-03-12 | 山东中科嘉亿生物工程有限公司 | 一种植物乳杆菌jylp-376及后生元菌剂、制备方法和应用 |
| CN117683698B (zh) * | 2024-02-04 | 2024-05-14 | 山东中科嘉亿生物工程有限公司 | 一种植物乳杆菌jylp-376及后生元菌剂、制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar et al. | Characterization of Lactobacillus isolated from dairy samples for probiotic properties | |
| CN108373984A (zh) | 一种副干酪乳杆菌及其应用 | |
| CN102206599B (zh) | 一种耐氧耐酸性长双歧杆菌 | |
| Iyer et al. | Probiotic properties of folate producing Streptococcus thermophilus strains | |
| CN105132322A (zh) | 一株植物乳杆菌及其应用 | |
| CN110564638A (zh) | 一株具有益生特性的罗伊氏乳杆菌及其用途 | |
| Slyvka et al. | Strains of lactic acid bacteria isolated from traditional Carpathian cheeses | |
| CN113403227A (zh) | 一株植物乳杆菌及其制备方法和应用 | |
| CN113151070B (zh) | 一株可提高肠道中克里斯藤森菌科相对丰度的发酵乳杆菌 | |
| Shafakatullah et al. | Screening of raw buffalo’s milk from Karnataka for potential probiotic strains | |
| CN117305169A (zh) | 一株链球菌及其应用 | |
| US11045507B2 (en) | Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30 | |
| CN107937316A (zh) | 空间罗伊氏乳杆菌Fullarton‑9‑71及应用 | |
| CN107974424A (zh) | 空间罗伊氏乳杆菌Fullarton-9-25及应用 | |
| CN107828703A (zh) | 空间罗伊氏乳杆菌Fullarton‑9‑35及应用 | |
| CN116064324B (zh) | 一株鼠李糖乳杆菌及其培养方法和在防治腹泻和肠炎方面的应用 | |
| KR100240687B1 (ko) | 락토바실러스 애시도필러스 ky 2104 및 그 용도 | |
| EP3318625B1 (en) | A lactic acid bacteria strain | |
| JP4457364B2 (ja) | 新規な乳酸菌及び当該乳酸菌を使用して加工した各種製品 | |
| CN114262680B (zh) | 菌株及其应用 | |
| CN115612637B (zh) | 一株植物乳杆菌及其应用 | |
| CN113604387B (zh) | 一株耐盐、耐高温罗伊氏乳杆菌及其在畜禽水产养殖中防治病原菌的应用 | |
| CN111004735A (zh) | 一株发酵乳杆菌及其在改善肠道健康方面的应用 | |
| CN115612637A (zh) | 一株植物乳杆菌及其应用 | |
| CN107974425A (zh) | 空间罗伊氏乳杆菌Fullarton-9-79及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |